ABOUT RECEPTOR LIFE SCIENCES

Receptor Life Sciences is a pharmaceutical company that applies FDA-approved drug-delivery technologies to develop innovative therapies to address central nervous system disorders that have few safe and effective treatments. Receptor Life Sciences uses these technologies to produce inhaled and oral cannabinoid products that hold the potential to provide precision, consistency, reliability, and convenience.

OUR TECHNOLOGIES

Receptor's delivery technologies, used in both inhaled and oral FDA-approved prescription drug products, are a validated solution for the three main challenges of cannabinoid medicine: low absorption, poor bioavailability, and inconsistent dosing.

PIPELINE

Receptor Life Sciences is committed to developing our product candidates according to FDA standards. The approach for each product candidate is based on its scientific and medical rationale, a market analysis and feedback received from the FDA.

Our Team

Receptor Life Sciences has a team of dedicated leaders with decades of experience in research, drug delivery technologies, pre-clinical, clinical and commercialization of innovative therapies that fill unmet medical needs.

Mark Theeuwes

Mark is a healthcare executive with more than 20 years of experience. He has a wide range of focus both on the clinical and commercial sides of the business within the rare diseases, Neurology, urology, pain, primary care, infectious disease and dental industries. Most recently, Mark served as Executive Vice President and Chief Operating Officer of Engage Therapeutics. Engage Therapeutics was in the process of developing Staccato® Alprazolam and if approved will be the first and only drug-device-combination for the rapid termination of an active epileptic seizure. Engage was sold to UCB in 2020 in a deal valued at $270 million following the successful completion of its randomized, phase 2b clinical study.

Previously, Mark served as Vice President of Sales, Trade and Commercial Operations at Egalet. As one of the first commercial employees, Mark was integral in establishing key functions within Trade, Commercial Operations and Sales Excellence at Egalet in order to lead the launch of three products within the company’s first two years. Prior to that, he was an Executive Director of Decision Support and member of the U.S. Commercial Leadership team at NPS until it was acquired by Shire plc in 2015. Before this role at NPS, Mark headed up Sales Operations at ViroPharma until it was acquired by Shire plc in 2014.

Mark started his career as a sales representative at Alza, which was acquired by Johnson & Johnson in 2001. Over the next 10 years, Mark held a number of sales, training, operations and analytics positions of increasing responsibility within the Johnson & Johnson family of companies.

Andrea Leone-Bay, Ph.D.

Dr. Leone-Bay is an internationally recognized authority on inhaled dry powder and oral drug delivery technologies. She brings unparalleled pharmaceutical development and formulation expertise with 48 publications in peer-reviewed journals and 93 issued U.S. patents.

Formerly Vice President and head of pharmaceutical development for MannKind Corporation, Dr. Leone-Bay has decades of drug development experience. Among her achievements are two FDA-approved and currently marketed products. She is an experienced R&D manager having led corporate divisions dedicated to research, development and commercialization of regulated drug products and drug-device combinations.

Traci Carman

Ms. Carman is an experienced finance and operations executive whose strategic insight and expertise led to the financial growth and scalable operations of numerous corporations, non-profits, and startups across a range of industries. Ms. Carman’s track record includes securing several successful funding rounds, IPO financial reporting, and structuring and closing multiple critical financings for startup companies. Ms. Carman has led and scaled all aspects of finance, accounting, tax, FP&A, treasury, risk management, debt and equity financing, and mergers and acquisions.

Kelly S. Kraft, Ph.D.

Kelly S. Kraft has over 20 years of pharmaceutical industry experience in oral and inhaled drug delivery. Dr. Kraft leads Receptor's product development team from basic research through manufacturing, testing, release, and stability of Phase 1 clinical supplies. She also oversees the conduct of nonclinical and clinical studies, coordinates work at external CDMOs, and aligns internal and external work with Receptor's regulatory partner.

Prior to Receptor, Dr. Kraft was the director of pharmaceutical R&D at MannKind Corporation, supporting AFREZZA® inhaled insulin and product line extensions including Treprostinil Technosphere inhalation powder.

After earning her Ph.D. in medicinal chemistry at the University of Georgia, Dr. Kraft began her career at Emisphere Technologies, focused on the development of oral absorption enhancers.

Arthur Rubinfeld

As the former President, Starbucks, Mr. Rubinfeld was instrumental in building the company's development from IPO to the Fortune 150. He was responsible for global development, R&D, quality assurance, and regulatory compliance. Known for his leading-edge, visionary work in integrated brand positioning, marketing, and design across corporate divisions and platforms, Mr. Rubinfeld built Starbucks into one of the world's most recognizable brands.

Mr. Rubinfeld has extensive board experience and most recently served as Independent Director for United Capital, which was purchased in July 2019 by Goldman Sachs for $750M. He is Founder of AIRVISION Advisors, a strategic growth advisory firm and co-authored Built for Growth - Expanding Your Business Around the Corner or Across the Globe.

Business Week recognized Mr. Rubinfeld as one of the top "Candidates for the Corner Office" in their "CEOs of Tomorrow."

Gregory T. Mayes, J.D.

Gregory T. Mayes, J.D. is an accomplished biopharma executive and an expert in biopharmaceutical business strategy and commercialization. He currently serves as President, CEO and Director of Antios Therapeutics, where he leads development of drugs that have the potential to serve as the backbone of a curative regimen for Hepatitis B ("HBV").

Prior to his role at Antios, Mr. Mayes in 2017 founded Engage Therapeutics. As CEO of Engage Mr. Mayes lead the development of an inhaled alprazolam for the rapid cessation of seizures. Engage recently completed a successful Phase II efficacy study enabling a competitive sale to Belgian pharmaceutical giant UCB.

Before founding Engage Mr. Mayes served as Chief Operating Officer and Board member of Advaxis Immunotherapies. In this position he was instrumental in establishing major pharma partnerships. He also developed a Phase III registration strategy and clinical development plan for Advaxis's lead product candidate, resulting in an FDA Fast Track Designation.

Prior to Advaxis, Mr. Mayes served as President and General Counsel and Board member for Unigene Laboratories. At Unigene he led out-licensing efforts for a novel oral peptide drug delivery platform. Mr. Mayes also served as Vice President, General Counsel, and Chief Compliance Officer at ImClone Systems, where he contributed significantly to the clinical development and commercialization of ERBITUX® (cetuximab). He was also instrumental to the $6.5 billion-dollar sale of ImClone Systems to Eli Lilly in 2008.

Mr. Mayes also served as Senior Counsel at AstraZeneca Pharmaceuticals LP, where he provided a wide range of legal services in connection with the development and commercialization of five approved products in AstraZeneca's oncology portfolio. Mr. Mayes is a cum laude graduate of Syracuse University where he was recognized as a Remembrance Scholar. He earned his J.D. degree magna cum laude from Temple University School of Law, where he was the Articles Editor on the Temple Law Review.

James B. Weissman

James B. Weissman, Executive Vice President and Chief Operating Officer, Dicerna Pharmaceuticals. Mr. Weissman has more than 30 years’ experience in the life sciences industry, with extensive international management experience in biotech and pharmaceutical general management, product development, licensing, business development, marketing and M&A activities. At Dicerna, Mr. Weissman leads alliance management, business development, corporate communications, corporate operations, and new product planning.

Prior to Dicerna, Mr. Weissman was vice president of business development at MannKind Corporation, responsible for leading the company’s activities related to licensing, new products and strategic planning. Mr. Weissman held leadership positions in both business development and marketing at Pfizer Pharmaceuticals, Inc. in Tokyo, most recently as senior director of marketing. In that position, he was responsible for the sales, profit and strategic targets for the company’s specialty products, including central nervous system, endocrinology, ophthalmology and oncology therapeutics and diversified portfolios.

Traci Carman

Ms. Carman is an experienced finance and operations executive whose strategic insight and expertise led to the financial growth and scalable operations of numerous corporations, non-profits, and startups across a range of industries. Ms. Carman’s track record includes securing several successful funding rounds, pre-IPO financial reporting, and structuring and closing multiple critical financings for startup companies. Ms. Carman has led and scaled all aspects of finance, accounting, tax, FP&A, treasury, risk management, debt and equity financing, and M&A.

Gregory F. Wesner

Mr. Wesner is a leading intellectual property attorney and corporate growth strategist with decades of experience in pharmaceutical and life sciences companies. He has designed and implemented IP-driven strategies to power growth, financing, mergers and acquisitions, and public offerings.

Mr. Wesner identified the potential for immediate onset inhaled dry powder cannabinoid drugs, forging the exclusive Receptor-Mannkind global partnership. He also contributed to developing Receptor’s oral delivery technology that facilitates enhanced bioavailability of orally administered cannabinoid drugs. Receptor has adapted and patented its oral delivery technology for the global cannabinoid market.

Super Lawyer Washington Magazine has recognized Mr. Wesner yearly since 2007, and is recognized by Best Lawyers in America for his intellectual property expertise.

Mark Theeuwes

Mark is a healthcare executive with more than 20 years of experience. He has a wide range of focus both on the clinical and commercial sides of the business within the rare diseases, Neurology, urology, pain, primary care, infectious disease and dental industries. Most recently, Mark served as Executive Vice President and Chief Operating Officer of Engage Therapeutics. Engage Therapeutics was in the process of developing Staccato® Alprazolam and if approved will be the first and only drug-device-combination for the rapid termination of an active epileptic seizure. Engage was sold to UCB in 2020 in a deal valued at $270 million following the successful completion of its randomized, phase 2b clinical study.

Previously, Mark served as Vice President of Sales, Trade and Commercial Operations at Egalet. As one of the first commercial employees, Mark was integral in establishing key functions within Trade, Commercial Operations and Sales Excellence at Egalet in order to lead the launch of three products within the company’s first two years. Prior to that, he was an Executive Director of Decision Support and member of the U.S. Commercial Leadership team at NPS until it was acquired by Shire plc in 2015. Before this role at NPS, Mark headed up Sales Operations at ViroPharma until it was acquired by Shire plc in 2014.

Mark started his career as a sales representative at Alza, which was acquired by Johnson & Johnson in 2001. Over the next 10 years, Mark held a number of sales, training, operations and analytics positions of increasing responsibility within the Johnson & Johnson family of companies.

Dr. Devinsky is the Director of the New York University (NYU) Comprehensive Epilepsy Center and the Saint Barnabas Institute of Neurology and Neurosurgery. He is also a Professor of Neurology, Neurosurgery, and Psychiatry at NYU Langone School of Medicine. Dr. Devinsky specializes in epilepsy and behavioral neurology.

He serves as a reviewer for more than 30 journals and is a key member of several Scientific Advisory Boards across the pharmaceutical industry. Dr. Devinsky has published more than 500 articles and book chapters and has led multiple antiepileptic clinical trials. He has current research support from NINDS, NIMH, NIBIB, DoD, MURI, National Science Foundation and Simmons Foundation.

In the field of cutting-edge cannabinoid research, Dr. Devinsky served as a principal investigator for the development of GW Pharmaceuticals' Epidiolex® (cannabidiol) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy.

Morse Alumni Distinguished Teaching Professor of Pharmacy and Neurology, the Lawrence C. Weaver Endowed Chair in Orphan Drug Development, and Director of the Center for Orphan Drug Research at the University of Minnesota College of Pharmacy.

Dr. Cloyd’s research focuses on the clinical pharmacology of CNS drugs. His research includes laboratory investigations of drug solubility, stability, and pharmacology; pharmacokinetic and efficacy studies in animals; drug safety, bioavailability and pharmacokinetic, pharmacogenomic, drug interaction, and efficacy studies in healthy volunteers and/or patients including children and the elderly. He holds 9 INDs and has served as principal or co-principal investigator for several Phase I-Phase III trials, many of which have supported NDA applications.

He has been a member of several National Institute of Neurological Disorders and Stroke (NINDS) data and safety monitoring boards, has served on the NINDS clinical trials study section, and is a temporary voting member of the FDA Advisory Committee on Pharmaceutical Science and Clinical Pharmacology.

Associate Professor of Neurology at NYU Langone Health. His expertise includes epilepsy, clinical trial methodology, novel trial designs, and outcomes research.

Dr. Friedman is also the co-director of the video-EEG (electroencephalography) laboratory at NYU Langone Health. Dr. Friedman specializes in the treatment of teenagers and adults with difficult to control epilepsy. He also performs research to better understand the causes of morbidity and mortality of epilepsy and test interventions to improve outcomes.

He serves on the executive committees of the North American SUDEP (sudden unexpected death in epilepsy) Registry and the Epilepsy Study Consortium. He also serves on the professional advisory board of the Epilepsy Foundation.

Chief Medical Officer, the National Collegiate Athletic Association, and Clinical Professor of Neurology at Indiana University School of Medicine and NYU School of Medicine. He is an expert in pain management, concussion and sports medicine.

Dr. Hainline serves as the NCAA’s first chief medical officer, where he oversees the NCAA Sport Science Institute, which works collaboratively with member institutions and Centers of Excellence across the United States.

For more than 25 years, Dr. Hainline has been actively involved in sports medicine. He co-authored “Drugs and the Athlete,” and played a pivotal role in the development of drug testing and education protocols worldwide. He has served on the New York State Athletic Commission and the USOC Sports Medicine Committee and is a founding member of the executive committee of the American Academy of Neurology Sports Neurology Section that he currently chairs.

At the NCAA, Dr. Hainline developed, in partnership with the Department of Defense, the NCAA-DoD Grand Alliance, which includes the CARE Consortium, a multimillion-dollar study that aims to understand the natural history of concussion and neurobiological recovery in concussion. Dr. Hainline has taken a leadership role in addressing other pressing issues of student-athletes, including mental health, overuse injuries, alcohol and drug abuse, and sudden cardiac death.

Edwin S. Lowe Professor and Vice Chair of Neurology, Professor of Epidemiology and Population Health and Professor of Psychiatry and Behavioral Sciences at the Albert Einstein College of Medicine. He directs the Montefiore Headache Center.

Dr. Lipton earned his medical degree at the University of Chicago Pritzker School of Medicine.

After a medical internship at Northwestern Memorial Hospital, he completed his neurology residency and clinical neurophysiology fellowship at the Albert Einstein College of Medicine. He also completed a fellowship in neuroepidemiology at Columbia University. He is a diplomate of the American Board of Psychiatry and Neurology and a fellow of the American Academy of Neurology.

His research focuses on cognitive aging, Alzheimer’s disease and migraine headaches. He is the Principal Investigator of the Einstein Aging Study, an NIH funded Program Project. His research focuses on risk factors and biomarkers of cognitive decline and Alzheimer’s disease. His recent studies examine cognitive aging across the lifespan with an emphasis on the effects of pain and stress on brain function.

His headache research focuses on the epidemiology of migraine and on clinical trials. His epidemiologic studies have evaluated trigger factors for headache attacks and risk factors for headache progression. Dr. Lipton has published more than 800 original articles, many with trainees. He is a five-time winner of the H.G. Wolff Award for excellence in headache research from the American Headache Society and a two-time winner of the Enrico Greppi award from the European Headache Federation. Dr. Lipton is Director of the Montefiore Headache Center, an interdisciplinary subspecialty center focused on headache, patient care, research and education.

Lucius N. Littauer Professor and Chair of the Department of Psychiatry at NYU Langone Health. Dr. Marmar directs the NYU Center for the Study of Alcohol Use Disorder and Posttraumatic Stress Disorder. He is an international expert in anxiety disorders, PTSD, and mental health in veterans.

Dr. Marmar previously served as Professor and Vice Chair at the University of California, San Francisco (UCSF), and the Associate Chief of Staff for Mental Health and Director of the Posttraumatic Stress Disorder (PTSD) Research Program at the San Francisco Veterans Affairs Medical Center.

Internationally-renowned for his expertise in PTSD, Dr. Marmar's focus has ranged from combat-related conditions in veterans, including those from Iraq and Afghanistan, to groups as disparate as refugees and earthquake victims. He has served on multiple committees and scientific advisory groups at the national level, for both the Veteran's Administration in Washington, D.C., and for the National Institute of Mental Health.

An award-winning teacher and researcher who chaired his department's Research and Education Track at UCSF and directed a VA Neuroscience Research Fellowship program, Dr. Marmar is currently the principal investigator of seven PTSD-related grants funded by the National Institute on Alcohol Abuse and Alcoholism, the Department of Defense, Bank of America Foundation and Brockman Foundation.

PRESS RELEASES